TY - JOUR
T1 - The prognostic impact of jumonji domain-containing 2b in patients with resected lung adenocarcinoma
AU - Toyokawa, Gouji
AU - Taguchi, Kenichi
AU - Edagawa, Makoto
AU - Shimamatsu, Shinichiro
AU - Toyozawa, Ryo
AU - Nosaki, Kaname
AU - Hirai, Fumihiko
AU - Yamaguchi, Masafumi
AU - Shimokawa, Mototsugu
AU - Seto, Takashi
AU - Takenoyama, Mitsuhiro
AU - Hamamoto, Ryuji
AU - Sugio, Kenji
AU - Ichinose, Yukito
PY - 2016/9
Y1 - 2016/9
N2 - Background: Jumonji domain-containing 2B, JMJD2B, has been shown to play an important role in the pathogenesis of lung cancer cells. However, the significance of JMJD2B in patients with lung cancer remains to be elucidated. Patients and Methods: Seventy-eight patients with resected adenocarcinoma, whose data regarding oncogenic drivers in lung cancer were available, were included in the study. Immunohistochemical analysis was performed with a specific antibody for JMJD2B to investigate JMJD2B expression and the significance of JMJD2B expression in survival after surgery was evaluated. Results: Among the 78 patients, 50 (64%) exhibited JMJD2B immunopositivity. The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7% vs. 92.6%; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor. Conclusion: JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma.
AB - Background: Jumonji domain-containing 2B, JMJD2B, has been shown to play an important role in the pathogenesis of lung cancer cells. However, the significance of JMJD2B in patients with lung cancer remains to be elucidated. Patients and Methods: Seventy-eight patients with resected adenocarcinoma, whose data regarding oncogenic drivers in lung cancer were available, were included in the study. Immunohistochemical analysis was performed with a specific antibody for JMJD2B to investigate JMJD2B expression and the significance of JMJD2B expression in survival after surgery was evaluated. Results: Among the 78 patients, 50 (64%) exhibited JMJD2B immunopositivity. The overall survival (OS) of the 50 JMJD2B-positive patients after surgery was significantly inferior to that of the JMJD2B-negative patients (five-year survival=56.7% vs. 92.6%; log-rank: p=0.01). Multivariate analysis showed that JMJD2B positivity was an independent prognostic factor. Conclusion: JMJD2B may be a novel prognostic factor for resected lung adenocarcinoma.
UR - http://www.scopus.com/inward/record.url?scp=84991698841&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84991698841&partnerID=8YFLogxK
U2 - 10.21873/anticanres.11046
DO - 10.21873/anticanres.11046
M3 - Article
C2 - 27630338
AN - SCOPUS:84991698841
VL - 36
SP - 4841
EP - 4846
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 9
ER -
